Khosla Divya, Kumar Ritesh, Kapoor Rakesh, Kumar Narendra, Bera Anjan, Sharma Suresh C
Department of Radiotherapy and Oncology, Regional Cancer Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh, 160012, India.
J Gastrointest Cancer. 2013 Dec;44(4):417-21. doi: 10.1007/s12029-013-9519-1.
Primary intestinal lymphomas comprise of a wide variety of histological subtypes with varied presentation. The objective of this study was to determine the presentation, histological type, treatment, and outcome of patients of primary intestinal lymphoma.
A retrospective analysis of 27 patients of primary intestinal lymphoma treated at our institute from 2004 to 2010 was carried out. Patients were staged according to Musshoff's modification of Ann Arbor classification.
The median age was 51 years (range, 7-76 years). Abdominal pain was the most common presenting symptom followed by mass abdomen, loss of appetite, constipation, and vomiting. The most common site of disease presentation was ileocecal region and jejunum. Diffuse large B cell lymphoma was the predominant histological type observed in 55.6%. Eighteen patients underwent surgery with or without chemotherapy. Chemotherapy, either alone or with radiotherapy, was given to nine patients. The median follow-up was 48.3 months (range 5-94 months). The 5-year overall survival (OS) and event-free survival were 53.5 and 53%, respectively. The 5-year OS for patients who underwent both surgery and chemotherapy was 79.5% and for those without surgery was 13.9%, respectively.
Primary intestinal lymphomas are heterogenous diseases. Patients who underwent surgery had better survival and outcome than those without surgery. Chemotherapy is necessary for improving the survival of these patients. Optimal management is still uncertain due to the rarity of this disease.
原发性肠道淋巴瘤包含多种组织学亚型,临床表现各异。本研究的目的是确定原发性肠道淋巴瘤患者的临床表现、组织学类型、治疗方法及预后。
对2004年至2010年在我院接受治疗的27例原发性肠道淋巴瘤患者进行回顾性分析。患者根据Ann Arbor分类法的Musshoff改良版进行分期。
中位年龄为51岁(范围7 - 76岁)。腹痛是最常见的首发症状,其次是腹部肿块、食欲不振、便秘和呕吐。疾病最常见的发生部位是回盲部和空肠。弥漫性大B细胞淋巴瘤是最主要的组织学类型,占55.6%。18例患者接受了手术,部分患者联合或未联合化疗。9例患者接受了单纯化疗或化疗联合放疗。中位随访时间为48.3个月(范围5 - 94个月)。5年总生存率(OS)和无事件生存率分别为53.5%和53%。接受手术和化疗的患者5年OS为79.5%,未接受手术的患者为13.9%。
原发性肠道淋巴瘤是异质性疾病。接受手术的患者比未接受手术的患者生存率和预后更好。化疗对于提高这些患者的生存率是必要的。由于这种疾病罕见,最佳治疗方案仍不确定。